Exposures
OtherCOVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
NCT Number: NCT06168019
This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.
Interested in participating?
Request Info18 year–50 year
Female
Observational
Government. Medical College Hospital, Nagpur, India
All pregnant women enrolled in the study will receive standard of care throughout their pregnancy, labor and delivery and post-partum to discharge. Wherever possible, study visits will coincide with regular antenatal (ANC) care and blood draws will be added to standard blood draws during ANC, labor and delivery and postpartum care. Women will be counselled about procedure to reduce the risk of acquiring ORV during pregnancy. Since this study is observational, we do not anticipate any specific safety concerns with study interviews and procedures, but the investigators will monitor potential adverse events to determine if they are likely or possibly study related.
PRIMARY OBJECTIVE: Determine the prevalence, incidence, and maximal severity of symptomatic or asymptomatic COVID-19 in pregnant women to day 42 postpartum/after miscarriage on maternal outcomes. Secondary analysis will evaluate whether influenza/Other Respiratory Viruses (ORV) infection or COVID-19 vaccination modifies or mediates this risk.
SECONDARY OBJECTIVE: Determine the effect of maternal COVID-19 infection on the fetus and/or neonate during pregnancy through day 7 of life. Secondary analysis will focus on whether influenza/ORV or vaccination modifies, and pre-term birth mediates this risk.
EXPLORATORY OBJECTIVE: Characterize patterns and trajectories of host response/ inflammatory biomarkers as potential mediators of COVID-19 ± Influenza and ORV infection on progression to severe illness in pregnant women/mothers admitted to Government Medical College hospital with COVID-19. Modifiers include COVID-19 , Influenza and other ORV vaccinations.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Women aged 18 to 50 years registering for antenatal care (ANC) at Government Medical College Hospital (GMC) Nagpur, India
Exclusion criteria
COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
Time frame: 1 year
The maternal composite variable includes any of following 3 outcomes:
Time frame: 1 year
The perinatal adverse outcomes includes any of the following 3 outcomes:
Contact information is provided by the study sponsor or research team.
Aboli Goghari, MPH
CONTACT
Patricia Hibberd, MD PhD
CONTACT
Boston University
Other
Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE) Study in India
Acronym: ICOPE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05266222
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT06417762
Behavior, COVID-19
Chicago, Illinois, United States
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07149428
Anosmia, Behavior
Bethesda, Maryland, United States
View Trial Details